Rajendra Maharaj, NP
Nurse Practitioner · Atlanta, GANPI 1235237611
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 24.2% of the total. Reporting peaked in 2023 at $155 and has fallen 76.7% since, to $36 in 2025.
Across 16 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$71
- Shield Therapeutics Inc$49
- Pfizer$42
- Amgen$30
- Exact Sciences$28
- Novo Nordisk$22
- plus $54 from 3 others
What the payments were for
- Food & beverage$296100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $71 |
| Shield Therapeutics Inc | 2 | $49 |
| Pfizer | 2 | $42 |
| Amgen | 2 | $30 |
| Exact Sciences | 2 | $28 |
| Novo Nordisk | 1 | $22 |
| Bayer | 1 | $21 |
| Lilly USA, LLC | 1 | $18 |
| GSK | 1 | $14 |
How this compares
$296 in reported general payments places this provider in the 60th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CefuroximeCefuroxime Axetil | 37 | $548 |
| Prednisone | 56 | $284 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 26 | $283 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $210 |
| Azithromycin | 35 | $199 |
| Doxycycline Monohydrate | 17 | $198 |
| Nabumetone | 16 | $181 |
| Meloxicam | 15 | $75 |
| Methocarbamol | 11 | $60 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Atlanta
- Janice McAlisterAtlanta$221K
- Laura ElledgeAtlanta$177K
- Casey MillerAtlanta$41K
- Kathryn InanAtlanta$17K
- Colby DoepelAtlanta$16K
- Mark HebertAtlanta$15K
- Ashley BlackmonAtlanta$13K
- Alexia CovingtonAtlanta$13K
- Marissa TorresAtlanta$12K
- Hayley TurnerAtlanta$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.